Neurologic Diseases and Neurogenetics

Antonio Martinez Yelamos

PRINCIPAL INVESTIGATORS
  • Serge Jauma Classen
  • Monica Povedano Panades
  • Ramon Reñe Ramirez
  • Joan Prat Rojo
  • Jordi Gascon Bayarri
  • Lucia Aja Rodriguez
  • Matilde Calopa Garriga
  • Pere Cardona Portela
  • Mercedes Falip Centellas
  • Júlia Miró Lladó
  • Sergio Martinez Yelamos
CLINICAL RESEARCHERS
  • Blanca Lara Rodriguez
  • Velina Nedkova Hristova
  • Andres Julian Paipa Merchan
  • Elisabet Romero Gangonells
  • Raul Dominguez Rubio
  • Laura Gonzalez Mera
  • Mariano Huerta Villanueva
  • Elisabet Matas Martin
  • Helena Quesada Garci
  • Sara Yagüe Jimeno
  • Jaume Campdelacreu Fumadó
  • Dolores Dot Bach
  • Isabel Fernandez Conejero
  • Lucia Romero Pinel
  • Pere Domenech Santasusana
  • Maria Isabel Leon Moreno
  • Misericordia Veciana De Las Heras
  • Laura Bau Vila
PREDOCTORAL RESEARCHERS
  • Silvia Muñoz Quiñones
  • Laura Diez Porras
  • Carla Marco Cazcarra
  • Albert Muñoz Vendrell
  • Roser Gomez Llopico
SCIENTIFIC SUPPORT
  • Abdelilah Assialioui Essanhaji
  • Sheila Álvarez Fornieles
MANAGEMENT SUPPORT
  • Susana Pobla Müller
  • José Luis Moreno Morejón
  • Cristina Terrafeta Pastor
Neuroscience
Neuroscience

Scientific production

68

PAPERS

Impact factor: 332,4

16 PUBLICATIONS IN FIRST DECILE

35 PUBLICATIONS IN FIRST QUARTILE

47 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Munoz Vendrell A, Sala Padro J, Jaraba S, Reynes Llompart G, Veciana M, Mora J, Falip M. Functional neuroimaging in nonepileptiform electroencephalographic patterns in status epilepticus. Acta Neurol. Scand. 2021;144(6):687-694. doi:10.1111/ane.13515. IF:3,21.
  • Gifreu A, Falip M, Sala Padro J, Mongay N, Morandeira F, Camins A, Naval Baudin P, Veciana M, Fernandez M, Pedro J, Garcia B, Arroyo P, Simo M. Risk of Developing Epilepsy after Autoimmune Encephalitis. Brain Sci. 2021;11(9):doi:10.3390/brainsci11091182. IF:3,39.
  • Andres Benito P, Gelpi E, Jove M, Mota Martorell N, Obis E, Portero Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol. Appl. Neurobiol. 2021;47(4):544-563. doi:10.1111/nan.12681. IF:8,09.
  • Alemany M, Nunez A, Falip M, Lara B, Paipa A, Quesada H, Mora P, de Miquel MA, Barranco R, Pedro J, Cardona P. Acute symptomatic seizures and epilepsy after mechanical thrombectomy. A prospective long-term follow-up study. SEIZURE-EUR J EPILEP. 2021;895-9. doi:10.1016/j.seizure.2021.04.011. IF:3,18.
  • Andrés Benito P, Domínguez R, Colomina MJ, Llorens F, Povedano M, Ferrer I. Correction for: YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging-US. 2021;13(20):23871-23871. doi:10.18632/aging.203667. IF:5,68.

Research highlights

PROJECTS

3 Competitive projects

1 Non-competitive project
56 clinical trials

INNOVATION

1 Patent

PUBLISHED WORKS

1 Clinical guideline

Selected projects

  • 18PSJ028. Activation of the resolution programs of inflammation as a novel therapeuthic approach for the treatment of amyotrophic lateral sclerosis. (HR17-00777). FUNDACIÓ “LA CAIXA”; FUNDACIO IDIBELL; FUNDACION MANUEL PEREZ (FMP); UNIV. AUTONOMA BARCELONA. 2018-2022. IP:POVEDANO PANADES,MONICA.
  • 18MAR003. ADDRESSING CHALLENGES OF STROKE CARE IN THE XXIst CENTURY: REACHING REPERFUSION THERAPY TOP RATES, ELIMINATING INEQUALITIES IN ACCESS AND DEALING WITH BIG DATA. (201712-32). BARCELONA SUPERCOMPUTING CENTER – CENTRO NACIONAL DE SUPERCOMPUTACION (BSC-CNS); FUNDACIÓ ICTUS; FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,ANTONIO.
  • 18MAR002. The Chemical Optimization of Cerebral Embolectomy (CHOICE) Trial. (201707-31). FUND. CLINIC PER RECERCA BIOMEDICA; FUNDACIO IDIBELL; FUNDACIÓ IMIM; FUNDACIÓ INSTITUT DE RECERCA VALL D’HEBRON; FUNDACIÓ LA MARATÓ DE TV3. 2018-2021. IP:MARTINEZ YELAMOS,SERGIO.
  • ACL:2022-010-1. A PHASE 3, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RELDESEMTIV IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). (CY5031). CYTOKINETICS, INC. 2021IP:MONICA POVEDANO PANADES.
  • ACL:2021-080-1. ESTUDIO DE FASE III DE NO INFERIORIDAD, ALEATORIZADO, ABIERTO, DE GRUPOS PARALELOS Y MULTICÉNTRICO PARA INVESTIGAR LA FARMACOCINÉTICA, LA FARMACODINÁMICA, LA SEGURIDAD Y LOS EFECTOS RADIOLÓGICOS Y CLÍNICOS DE OCRELIZUMAB SUBCUTÁNEO EN COMPARACIÓN CON OCRELIZUMAB INTRAVENOSO EN PACIENTES CON ESCLEROSIS MÚLTIPLE. (CN42097). ROCHE FARMA S.A. 2021IP:SERGIO MARTINEZ YELAMOS.